Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.42 |
| ▸ | BTK | Q06187 | 4/20 | 0.39 |
| ▸ | ITK | Q08881 | 4/20 | 0.39 |
| ▸ | BMX | P51813 | 1/20 | 0.39 |
| ▸ | BCL6 | P41182 | 2/20 | 0.37 |
| ▸ | ULK1 | O75385 | 1/20 | 0.36 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1740959 | 0.97 | EGFR (0.41) | EGFRBTKITKBMXBCL6 | |
| SCHEMBL1742693 | 0.93 | EGFR (0.41) | EGFRBTKITKBMXBCL6 | |
| SCHEMBL1741007 | 0.93 | EGFR (0.41) | EGFRBTKITKBMXBCL6 | |
| SCHEMBL1741009 | 0.93 | EGFR (0.41) | EGFRBTKITKBMXBCL6 | |
| SCHEMBL3506181 | 0.91 | PRKCQ (0.45) | EGFRBTKITKBMXBCL6 | |
| SCHEMBL1740983 | 0.90 | EGFR (0.39) | EGFRBTKITKBCL6ULK1 | |
| SCHEMBL3506019 | 0.90 | EGFR (0.46) | EGFRBTKITKBMXBCL6 | |
| SCHEMBL1741022 | 0.88 | PRKCQ (0.47) | EGFRBTKITKBMXBCL6 | |
| SCHEMBL1740833 | 0.88 | EGFR (0.48) | EGFRBTKITK | |
| SCHEMBL1741337 | 0.88 | ALK (0.43) | EGFRBTKITKBMX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130210810-A1 | Protein Kinase C Inhibitors and Uses Thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2013-08-15 | — | — | US | claimed |
| EP-2389373-A1 | DERIVATIVES OF N2-(3-PYRIDIL OR PHENYL)-N4-(4-PIPERIDYL)-2,4-PYRIMIDINEDIAMINE USEFUL IN THE TREATMENT OF INFLAMMATORY, AUTOIMMUNE OR PROLIFERATIVE DISEASES | Rigel Pharmaceuticals, Inc. (US) | 2011-11-30 | — | — | EP | claimed |
| US-20110253835-A1 | AIRCRAFT INTERIOR LAVATORY | BE INTELLECTUAL PROPERTY, INC. (US) | 2011-10-20 | — | — | US | claimed |
| WO-2010090875-A1 | DERIVATIVES OF N2-(3-PYRIDIL OR PHENYL)-N4-(4-PIPERIDYL)-2,4-PYRIMIDINEDIAMINE USEFUL IN THE TREATMENT OF INFLAMMATORY, AUTOIMMUNE OR PROLIFERATIVE DISEASES | RIGEL PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | claimed |
| US-20100204208-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2010-08-12 | — | — | US | claimed |
| US-9149475-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20130210810-A1 | Protein Kinase C Inhibitors and Uses Thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-8377924-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS INC. (US) | 2013-02-19 | — | — | US | disclosed |
| EP-2389373-A1 | DERIVATIVES OF N2-(3-PYRIDIL OR PHENYL)-N4-(4-PIPERIDYL)-2,4-PYRIMIDINEDIAMINE USEFUL IN THE TREATMENT OF INFLAMMATORY, AUTOIMMUNE OR PROLIFERATIVE DISEASES | Rigel Pharmaceuticals, Inc. (US) | 2011-11-30 | — | — | EP | disclosed |
| US-20110253835-A1 | AIRCRAFT INTERIOR LAVATORY | BE INTELLECTUAL PROPERTY, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| WO-2010090875-A1 | DERIVATIVES OF N2-(3-PYRIDIL OR PHENYL)-N4-(4-PIPERIDYL)-2,4-PYRIMIDINEDIAMINE USEFUL IN THE TREATMENT OF INFLAMMATORY, AUTOIMMUNE OR PROLIFERATIVE DISEASES | RIGEL PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| US-20100204208-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204208-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | PRKCH, PRKCA, PRKCB | EGFR 2299/4885BTK 248/4885ITK 884/4885 |
| US-20130210810-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | EGFR 2299/4885BTK 248/4885ITK 884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.